{"name":"ImmunoVaccine Technologies, Inc. (IMV Inc.)","slug":"immunovaccine-technologies-inc-imv-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CPA","genericName":"CPA","slug":"cpa","indication":"Metastatic melanoma (in combination with checkpoint inhibitors)","status":"marketed"}]}],"pipeline":[{"name":"CPA","genericName":"CPA","slug":"cpa","phase":"marketed","mechanism":"CPA is a cancer immunotherapy vaccine that stimulates the immune system to recognize and attack cancer cells by presenting tumor-associated antigens.","indications":["Metastatic melanoma (in combination with checkpoint inhibitors)","Non-small cell lung cancer (in development)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPVGdwSUllaVY5cmdsN243X09uUUp0NkttaERnZXNlVk9UQmQ0dEhlRFBHLUhPUkZCLVktUXgxbndLdWxFcDdDSnFLZS04ZzhiaElxbmdJckp0UVdhbEE2QmhueV9OaERYSGdIUmY5OUtiVkphdnNwZjNwc3NXY1FPWlQzbklIbVZoU00yOG5fM0x2SkJDTkV3empBNlhubkRNQlRwQ0VzMA?oc=5","date":"2024-06-19","type":"pipeline","source":"BioSpace","summary":"U.S. Small Molecule Innovator API CDMO Market Size to Reach USD 15.48 Bn by 2033 - BioSpace","headline":"U.S. Small Molecule Innovator API CDMO Market Size to Reach USD 15.48 Bn by 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxOam9KMmthVDZ5NEdrcEpralZBcDdBOHlWX3lwYmI0MW9XTDVoeGdLdVBSbDYzdXcwR3BOaG5VcFVpdlViSllxNnU4T2swbFVrTHpUNmFsX09aazdKNUpyNzVTeGZKUXpIeGRDN3AzRVVRZDF3eU51TWg2dVFDV3RZOTc5V0J0X3B5SFNJU1A0aG00NmpUQzYtd0JHZ0gzRWlqWEZMNFMwTVVjQmdVamxrc29scGFuNmhic1JrZHl0ektVOEthVFlxbUFJN0lINmc4V2FCYzFBLWZsMnJuc1czZWJNYk82MC1sVHhRN0gxMXlPUjBObTc2MktzZE4xVGY5RmpOSlA0ZE5yN1hFZ3BRUUtCa3U2YU44SEhwS21vb1M3alMwOExJX3lBWUpxaUk?oc=5","date":"2024-02-21","type":"pipeline","source":"PR Newswire","summary":"BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC. - PR Newswire","headline":"BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL ST","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPUWxsR0RYUWp1NEhSeTlvQzNLZXM0cm1OTFdwZXR5VnhNS2k1MWxoT2owR0tBZF9pQlJPQzFrTEM0dTNqMVlvdTlYbVJTT3dIdWloNGJMM0lKV3FLYW4wRVVQNmVUdHhVTndWTDVKVHR2al9iRWc5TmNVV3FnTWRLYlFsZw?oc=5","date":"2024-02-15","type":"deal","source":"PharmTech.com","summary":"BioVaxys Acquires Full Portfolio of Former IMV - PharmTech.com","headline":"BioVaxys Acquires Full Portfolio of Former IMV","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNSlJMSkVaMEZQSzMxQUdGOVBHTVdQNHdtbUFqRFB2WTdDb0JQemdwOU1iTVVXcVZxTEZCUGR5YlRIcGtzSFUyLWcwOUJsaTBaYmdNNnk3S3Y4TjNiem5mT1Nkem8wZmpNcUczZm1WRWdKMjdOdXFwNEc5dllxczNpSEpTVmJmVkgzOENZMGIxQjRTVzZZTHdTNHJxc1I0S1lJTkhBa3dtUTdvMkotT1NvVXhzVXk?oc=5","date":"2024-02-13","type":"pipeline","source":"Pharmaceutical Technology","summary":"BioVaxys snatches up ‘bankrupt’ IMV’s preclinical and clinical assets - Pharmaceutical Technology","headline":"BioVaxys snatches up ‘bankrupt’ IMV’s preclinical and clinical assets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNT0p1Z21fVlpqdmJxM1dLc0dydnF5YnpOVWowZmdMOGlTTlhHNWRwaVhGWHo3LVZiM3ktNUtHSV9wY0xaZkR0d01OREtGRjVRa2lrSy1HbVR5WFlSTUE4ejhxSVZSNWZ6ODQ0ZWtQX3RaWlNZTkZPUDNycW1LRTgwWnJBV1EwczRmNDRkTUxpNy1RdnRIbGNhb25IU1NVd3FTbjNSVHUtVl82T1BxbmJqaXYwdlhLUWNnZ05aSDh2MUE?oc=5","date":"2024-02-12","type":"deal","source":"Contract Pharma","summary":"BioVaxys Acquires IP, Immunotherapeutics Platform Technology & Assets of IMV Inc. - Contract Pharma","headline":"BioVaxys Acquires IP, Immunotherapeutics Platform Technology & Assets of IMV Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxPSGVJZ1ROU1ZyMVprY1VlYUtxVXRiM3l0aXFXSEs2ZzFHUW9XWjNEWVI3X0xRbE1UeHU4TVVZbGx0TjVxc1diNjNCNEVkR3FZNlRzYlZjQ0tDVXVmWkxDRy01anN1YUVTbk9ISG5UXy1xdW9mVVgxSmJJcW42VzFvc25vOTZVWl9fY0VBckFFYV91MXREOGQ2cWlqaHVJQkdxRkZ3S1huREwxS3ZCZFlXVUU5U09XV3JOMmRWRDNHOVMtU0ZuUDJsbXA0UVZIeHU5RFlqWE4zZC1SUWhKQnI0SzdPRjhmVUlUYnFwclZDQ3Y5SlpIQXVfSk5mLUlHSzNCbjFLN2RYakx2RlN4UHUtcHZvVC0?oc=5","date":"2024-02-12","type":"deal","source":"PR Newswire","summary":"BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc. - PR Newswire","headline":"BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Fo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNaGFRMHFFVlBvMWJDa2x0b1Fzb0FiVTBMVDFWem52YWRIS3V1a0RnUnQ4V0hpU2QtMTdMLTAyOC02LWV5dWd2NzZzNDlMTkhXRmxvazhVMUY4SERoV2E0YmxmNFBhR1J1N3BxNDN2anpSYXVfZlZXQXZYcW9OY2loMTVITDlZeW1GMEpibTg2TmNDaGVYX2ZLNjlqZk1leWR1ekE?oc=5","date":"2024-01-31","type":"deal","source":"Contract Pharma","summary":"Pharmaceutical Industry Mergers & Acquisitions Roundup - Contract Pharma","headline":"Pharmaceutical Industry Mergers & Acquisitions Roundup","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxQMEJoUXY5c21NYzhDMEZXOExvMnByd05TaTF1bVFWcmtpYU1lNl9mcUJCYVNmdFRoUjA4Q2p4SmtlZk0yeDA5TVBQbndmd0JUX1VLc01hVFJsQ1FCaEkteGtnT2hURzlxbXFuZUNvclJXWDVUbENDclJXOENNeUhweEFwTXJVdlBDaDJHcEVUS0h6TnBUUWQwYTZUbm9Dc0hJekhuSE9DNHFmOE9kSmVkT1F3MDYyRjg1Sm4wamhzT1h5eElVcE1ETDJCWnNPY2JIVUk5SExRYXhBcGdWSDBCSnhCcW9EdUQ4VE9XR2lOMmI4UzZGbDdV?oc=5","date":"2023-05-01","type":"pipeline","source":"Business Wire","summary":"IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic Alternatives - Business Wire","headline":"IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic Alternatives","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxOME9FUGQxbkRMTW1zTjBqaE04bVBYRFl6cERaWnRSVmg0OGJjY29RNkRsQXFjTmdON2VNd1FtYmZhOHJVcnhVSEpXYVJLaVRKWlFWS3VmSkwzM2hidW1JdWdvSUY2UHh1WWJGZWNlajlCNnM3TlJxbTlmNjFXVHE1dHFUSjliUGdiakNsR0pzaS1Bei1nWUFMSlc5UnlfNEgyODJxN25OLU1YcEQ4OUsydnJGZ0pyVDFnRngyTDNPMDNJOTFhanU4UHNFUVdWdWl6eUo5b2VEU3ZGdFhBcnJXeWd3VTVyUVJMeXJMWTI2U2Rrc2gwSEZvcFVPbjdSYk5C?oc=5","date":"2023-03-16","type":"earnings","source":"Business Wire","summary":"IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational Results - Business Wire","headline":"IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxQRUZTOEZHYWFiLVU2WThJeVRhUjQzaVJfNUxqTmdqV2JhUjluT2M1dEREQUZCQ1U2Rlh3WnF1UEcwZGxiU2JSV3YtUXFOYkkweWZZSWVIc3NLUU8xYnFGYTlhbl9mZlVrQ3ZaSUJYNHZKTEpTdEJVZUZyVlBNX2dzcUVQcEtFR1BjMVZ1WU9HNGYzdGxNOUw5bDdHSEtPMnozUGY5Y3REREktbDgzbnd1NTY5dEZHcnB3M3lfcHdSeG1NcU1xX1ZkTXZVWGxzRnB1VUd6RGFwR1FGcTVrSDYzcm8yRUpUWms?oc=5","date":"2022-12-16","type":"pipeline","source":"Business Wire","summary":"IMV Announces US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Business Wire","headline":"IMV Announces US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}